T he antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Video content above is prompted by the following: What are the main unmet needs for recurrent C difficile infections and how do you see the field evolving in the future?

What is in your differential diagnosis when considering recurrent C difficile infections? How is a definitive diagnosis made?

Purpose: Current and future treatment modalities for Clostridium difficile-associated disease (CDAD) are reviewed. Conclusion: CDAD is a major concern for health care systems and clinicians.

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix ... conditions first, but the potential for treatments is ...

Ferring Pharma has reported what it says is the first positive phase ... the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes ...

difficile or C. diff. In animal models, this first mRNA-LNP C ... difficile vaccines available, and the main treatment for ...